U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

On April 21, 2020, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (Imbruvica) in combination with rituximab (RITUXAN) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This approval expands the use of Imbruvica, which can already be administered as a single agent or in combination with obinutuzumab or bendamustine and rituximab for adult CLL/SLL patients.

“The approval of ibrutinib with rituximab as a frontline combination therapy represents an important advancement for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma,” said Meghan Gutierrez, Chief Executive Officer for the Lymphoma Research Foundation. “Each lymphoma patient’s experience is unique, and today’s approval offers patients with CLL/SLL a new treatment option and new opportunity for hope.”

For more information on the FDA approval of ibrutinib- rituximab (IMBRUVICA-RITUXAN), visit the FDA’s website or lymphoma.org/CLLFDAUpdates.


Update on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)
Thursday, April 30, 2020 | 2:30 – 3:30 PM ET

Register today >